Systemic inflammation in chronic obstructive pulmonary disease and asthma: Similarities and differences

Respirology

Volumn 13, Issue 1, 2008, Pages 128-133

  Higashimoto, Yuji ^a   Yamagata, Yuko ^a   Taya, Satoshi ^a   Iwata, Takuya ^a   Okada, Morihiro ^a   Ishiguchi, Tadashi ^a   Sato, Hiroaki ^a   Itoh, Hidekazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Alpha 1 antitrypsin; Asthma; Chronic obstructive pulmonary disease; Systemic inflammation; Transforming growth factor beta; Tumour necrosis factor alpha

Indexed keywords

ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ASTHMA; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE-PHASE PROTEINS; AGED; ASTHMA; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 38049165740     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2007.01170.x     Document Type: Article

References (22)

1. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J et al. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J. 2003 21 : 347 60.
2. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur. Respir. J. 2006 27 : 877 9.
3. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004 59 : 574 80.
4. Higashimoto Y, Yamagata Y, Iwata T, Okada M, Ishiguchi T et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur. Respir. J. 2005 25 : 885 90.
5. Szmigielski C, Raczkowska M, Styczynski G, Pruszczyk P, Gaciong Z. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur. Heart J. 2005 26 : 418 author reply 9.
6. Takemura M, Matsumoto H, Niimi A, Ueda T, Matsuoka H et al. High sensitivity C-reactive protein in asthma. Eur. Respir. J. 2006 27 : 908 12.
7. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001 163 : 1256 76.
8. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. Am. Rev. Respir. Dis. 1987 136 : 225 44.
9. Matsuse T, Fukuchi Y, Matsui H, Sudo E, Nagase T et al. Effect of cigarette smoking on pulmonary function in each phenotype M of alpha-1-protease inhibitor. Chest 1995 107 : 395 400.
10. Clark KD, Wardrobe-Wong N, Elliott JJ, Gill PT, Tait NP et al. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur. Respir. J. 1998 12 : 395 9.
11. American Thoracic Society. Standardization of spirometry, 1994 update. Am. J. Respir. Crit Care Med. 1995 152 : 1107 36.
12. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin. Radiol. 1982 33 : 379 87.
13. Engstrom G, Lind P, Hedblad B, Wollmer P, Stavenow L et al. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation 2002 106 : 2555 60.
14. Godoy I, Campana AO, Geraldo RR, Padovani CR, Paiva SA. Cytokines and dietary energy restriction in stable chronic obstructive pulmonary disease patients. Eur. Respir. J. 2003 22 : 920 5.
15. Yokoyama A, Kohno N, Fujino S, Hamada H, Inoue Y et al. Circulating interleukin-6 levels in patients with bronchial asthma. Am. J. Respir. Crit. Care Med. 1995 151 : 1354 8.
16. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: clinical manifestations and natural history. Thorax 2004 59 : 441 5.
17. Seyama K. State of alpha1-antitrypsin deficiency in Japan. Respirology 2001 6 (Suppl. S35 8.
18. Lind P, Engstrom G, Stavenow L, Janzon L, Lindgarde F et al. Risk of myocardial infarction and stroke in smokers is related to plasma levels of inflammation-sensitive proteins. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 577 82.
19. Gan WQ, Man SF, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005 127 : 558 64.
20. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, Muros de Fuentes M, Montejo de Garcini A et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur. Respir. J. 2006 27 : 902 7.
21. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003 107 : 1514 19.
22. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002 51 : 1596 600.